AU2001244166A1 - Farnesyl protein transferase inhibitor combinations with further anti-cancer agents - Google Patents

Farnesyl protein transferase inhibitor combinations with further anti-cancer agents

Info

Publication number
AU2001244166A1
AU2001244166A1 AU2001244166A AU4416601A AU2001244166A1 AU 2001244166 A1 AU2001244166 A1 AU 2001244166A1 AU 2001244166 A AU2001244166 A AU 2001244166A AU 4416601 A AU4416601 A AU 4416601A AU 2001244166 A1 AU2001244166 A1 AU 2001244166A1
Authority
AU
Australia
Prior art keywords
cancer agents
protein transferase
transferase inhibitor
farnesyl protein
further anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244166A
Inventor
Ivan David Horak
Peter Albert Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2001244166A1 publication Critical patent/AU2001244166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2001244166A 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents Abandoned AU2001244166A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200694 2000-02-29
EP00200694 2000-02-29
PCT/EP2001/002162 WO2001064252A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents

Publications (1)

Publication Number Publication Date
AU2001244166A1 true AU2001244166A1 (en) 2001-09-12

Family

ID=8171113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244166A Abandoned AU2001244166A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents

Country Status (6)

Country Link
US (1) US20030212008A1 (en)
EP (1) EP1261374A2 (en)
JP (1) JP2003525255A (en)
AU (1) AU2001244166A1 (en)
CA (1) CA2397448A1 (en)
WO (1) WO2001064252A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60118889T2 (en) * 2000-02-04 2006-11-30 Janssen Pharmaceutica N.V. FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR THE TREATMENT OF BREAST CANCER
AU2002352941A1 (en) * 2001-11-30 2003-06-17 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
BRPI0920927A2 (en) 2008-11-13 2019-09-24 Link Medicine Corp azaquinolinone derivatives and uses thereof
KR20150070348A (en) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. Heteroaryl linked quinolinyl modulators of rorγt
EA201590750A1 (en) 2012-10-16 2015-09-30 Янссен Фармацевтика Нв RELATED QUINOLINYL MODULATORS WITH PHENYL
JP6466335B2 (en) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ．ベー． ROR-γ-T methylene-linked quinolinyl modulators
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
WO2015057629A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US11642337B2 (en) 2017-11-08 2023-05-09 Tokyo Metropolitan Institute Of Medical Science Therapeutic agent for mental retardation or autism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5831115A (en) * 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CA2235986C (en) * 1995-11-06 2006-09-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
DE69620445T2 (en) * 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (IMIDAZOL-5-YL) METHYL-2-CHINOLINO DERIVATIVES AS A FARNESYL PROTEIN TRANSFERASE INHIBITOR
US6013662A (en) * 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CA2288140C (en) * 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
AU4562799A (en) * 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
IL143859A0 (en) * 1998-12-23 2002-04-21 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives

Also Published As

Publication number Publication date
JP2003525255A (en) 2003-08-26
WO2001064252A2 (en) 2001-09-07
WO2001064252A3 (en) 2002-03-21
US20030212008A1 (en) 2003-11-13
CA2397448A1 (en) 2001-09-07
EP1261374A2 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
AU2001240658A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001244166A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU2001254672A1 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
AU2001235496A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2001239275A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001246478A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001256166A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
IL143409A0 (en) Farnesyl protein transferase inhibitors
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU4228301A (en) Valve
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
IL163673A0 (en) Farnesyl protein transferase inhibitors as antitumor agents
AU2001244167A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
ZA200301545B (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors.
AU2001250321A1 (en) Homogentisate phytyl transferase
AU2001242434A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001272651A1 (en) Valves
NO20032471D0 (en) farnesyl transferase
PL348293A1 (en) Tricyclic farnesyl protein transferase inhibitors
PL355887A1 (en) Farnesyl transferase inhibitors
AU3514302A (en) 0ovel farnesyl protein transferase inhibitors
AU2002217962A1 (en) Death domain proteins
AU2002222249A1 (en) Valve